CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性白血病儿科患者 CAR-T 细胞治疗后的血浆微生物游离 DNA
英文原题：Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
查看英文原题
Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法是儿童复发/难治性 B 细胞急性淋巴细胞白血病（R/R B-ALL）的有前景治疗方法。细胞因子释放综合征（CRS）是 CAR-T 治疗后的常见毒性，发热往往是首发症状。CAR-T 治疗后区分 CRS 与感染可能较困难。血浆微生物游离细胞 DNA（mcfDNA）是一种新型诊断工具，可对 1,000 多种微生物进行定性和定量分析。本先导研究旨在描述儿童 R/R B-ALL 患者接受 CAR-T 治疗后前两个月的 mcfDNA 检测结果。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (R/R B ALL). Cytokine release syndrome (CRS) is a common toxicity after CAR T cell therapy and fever is often the first symptom.
Differentiating CRS from infection after CAR T cell therapy can be challenging. Plasma microbial cell free DNA (mcfDNA) is a novel diagnostic tool which allows for qualitative and quantitative assessment of over 1000 organisms. This pilot study sought to characterize mcfDNA results in pediatric patients with R/R B ALL in the first 2 months after CAR T cell therapy.
论文信息
- 作者
- Aftandilian C、Bito XR、Berman D、Zhang A、Duttagupta R、Davis KL
- 单位
- Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Stanford University, Palo Alto, California, USA.United States
- 期刊
- European journal of haematology2024 Aug
- 原文标识
- PubMed 38658354 · DOI 10.1111/ejh.14216